.png)
Prostate-specific Antigen (PSA) Testing Market by Type and Application- Global Industry Analysis & Forecast to 2027
Published On : November 2020 Pages : 158 Category: Pharma & Healthcare Report Code : HC1113451
SEGMENTS & REGIONS:
- Regions: North America, Europe, Asia- Pacific, Latin America, Middle East & Africa
Prostate-specific Antigen (PSA) Testing Market By Type (CLIA Method, ELISA Method) and Application (Screening, Post-treatment Monitoring, Other)- Global Industry Analysis & Forecast to 2027
Industry Outlook and Trend Analysis
The Prostate-specific Antigen (PSA) Testing Markethas encountered significant development over the recent years and is anticipated to grow tremendously over the forecast period.Prostate-specific Antigen (PSA) Testing measures the amount of prostate-specific antigen (PSA) in the blood. PSA is actually a protein produced by both cancerous and noncancerous tissue in the prostate, a small gland that sits below the bladder in men.
Drivers and Restraints
Top-down and bottom-up approaches are used to validate the global Prostate-specific Antigen (PSA) Testing Market and estimate the market size for company, regions segments, type segments and applications (end users). In the complete market engineering process, both top-down and bottom-up approaches were extensively used, along with several data triangulation methods, to perform market estimation and market forecasting for the overall market segments and sub segments listed in this report. Extensive qualitative and further quantitative analysis is also done from all the numbers arrived at in the complete market engineering process to list key information throughout the report.
Regional Insights
The data for 2021 is an estimate, based on the history data and the integrated view of industry experts, manufacturers, distributors and end users etc.
By Region
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- UK
- France
- Russia
- Italy
- Rest of Europe
- Asia-Pacific
- China
- Japan
- South Korea
- India
- Southeast Asia
- Rest of Asia-Pacific
- SouthAmerica
- Brazil
- Argentina
- Columbia
- Rest of South America
- Middle East and Africa
- Saudi Arabia
- UAE
- Egypt
- Nigeria
- South Africa
- Turkey
- Rest of MEA
Competitive Analysis
The major players in the market are profiled in detail in view of qualities, for example, company portfolio, business strategies, financial overview, recent developments, and share of the overall industry.
- Abbott
- Boston Scientific Corporation
- Bayer AG
- Siemens Healthcare
- DiaSorin
- Roche
- Beckman Coulter
- PerkinElmer
- Tosoh
Some of the key questions answered by the report are:
- What was the market size in 2017 and forecast from 2021 to 2027?
- What will be the industry market growth from 2017 to 2027?
- What are the major drivers, restraints, opportunities, challenges, and industry trends and their impact on the market forecast?
- What are the major segments leading the market growth and why?
- Which are the leading players in the market and what are the major strategies adopted by them to sustain the market competition?
Market Classification
· Prostate-specific Antigen (PSA) Testing Market, ByType, Estimates and Forecast, 2017-2027 ($Million)
o CLIA Method
o ELISA Method
· Prostate-specific Antigen (PSA) Testing Market, ByApplication, Estimates and Forecast, 2017-2027 ($Million)
o Screening
o Post-treatment Monitoring
o Other
· Prostate-specific Antigen (PSA) Testing Market, By Key Players, Estimates and Forecast, 2017-2027 ($Million)
o Abbott
o Boston Scientific Corporation
o Bayer AG
o Siemens Healthcare
o DiaSorin
o Roche
o Beckman Coulter
o PerkinElmer
o Tosoh
· Prostate-specific Antigen (PSA) Testing Market, By Region, Estimates and Forecast, 2017-2027 ($Million)
o North America
§ North America Prostate-specific Antigen (PSA) Testing Market, By Country
o U.S. Prostate-specific Antigen (PSA) Testing Market
o Canada Prostate-specific Antigen (PSA) Testing Market
o Mexico Prostate-specific Antigen (PSA) Testing Market
o Europe
§ Europe Prostate-specific Antigen (PSA) Testing Market, By Country
o UK Prostate-specific Antigen (PSA) Testing Market
o Germany Prostate-specific Antigen (PSA) Testing Market
o France Prostate-specific Antigen (PSA) Testing Market
o Russia Prostate-specific Antigen (PSA) Testing Market
o Italy Prostate-specific Antigen (PSA) Testing Market
o Rest of Europe Prostate-specific Antigen (PSA) Testing Market
o Asia-Pacific
§ Asia-Pacific Prostate-specific Antigen (PSA) Testing Market, By Country
o China Prostate-specific Antigen (PSA) Testing Market
o Japan Prostate-specific Antigen (PSA) Testing Market
o South Korea Prostate-specific Antigen (PSA) Testing Market
o India Prostate-specific Antigen (PSA) Testing Market
o Southeast Asia Prostate-specific Antigen (PSA) Testing Market
o Rest of Asia-Pacific Prostate-specific Antigen (PSA) Testing Market
o South America
§ South America Prostate-specific Antigen (PSA) Testing Market
o Brazil Prostate-specific Antigen (PSA) Testing Market
o Argentina Prostate-specific Antigen (PSA) Testing Market
o Columbia Prostate-specific Antigen (PSA) Testing Market
o Rest of South America Prostate-specific Antigen (PSA) Testing Market
o Middle East and Africa
§ Middle East and Africa Prostate-specific Antigen (PSA) Testing Market
o Saudi Arabia Prostate-specific Antigen (PSA) Testing Market
o UAE Prostate-specific Antigen (PSA) Testing Market
o Egypt Prostate-specific Antigen (PSA) Testing Market
o Nigeria Prostate-specific Antigen (PSA) Testing Market
o South Africa Prostate-specific Antigen (PSA) Testing Market
o TurkeyProstate-specific Antigen (PSA) Testing Market
o Rest of MEA Prostate-specific Antigen (PSA) Testing Market
1. Introduction
1.1. Report Description
2. Executive Summary
2.1. Key Highlights
3. Market Overview
3.1. Introduction
3.1.1. Market Definition
3.1.2. Market Segmentation
3.2. Market Dynamics
3.2.1. Drivers
3.2.2. Restraints
3.2.3. Opportunities
4. Market Analysis by Regions
4.1. North America (United States, Canada and Mexico)
4.1.1. United States Market Status and Outlook (2017-2027)
4.1.2. Canada Market Status and Outlook (2017-2027)
4.1.3. Mexico Market Status and Outlook (2017-2027)
4.2. Europe (Germany, France, UK, Russia, Italy and Rest of Europe)
4.2.1. Germany Market Status and Outlook (2017-2027)
4.2.2. France Market Status and Outlook (2017-2027)
4.2.3. UK Market Status and Outlook (2017-2027)
4.2.4. Russia Market Status and Outlook (2017-2027)
4.2.5. Italy Market Status and Outlook (2017-2027)
4.2.6. Rest of Europe Market Status and Outlook (2017-2027)
4.3. Asia-Pacific (China, Japan, Korea, India, Southeast Asia and Rest of Asia-Pacific)
4.3.1. China Market Status and Outlook (2017-2027)
4.3.2. Japan Market Status and Outlook (2017-2027)
4.3.3. Korea Market Status and Outlook (2017-2027)
4.3.4. India Market Status and Outlook (2017-2027)
4.3.5. Southeast Asia Market Status and Outlook (2017-2027)
4.3.6. Rest of Asia-Pacific Market Status and Outlook (2017-2027)
4.4. South America (Brazil, Argentina, Columbia and Rest of South America)
4.4.1. Brazil Market Status and Outlook (2017-2027)
4.4.2. Argentina Market Status and Outlook (2017-2027)
4.4.3. Columbia Market Status and Outlook (2017-2027)
4.4.4. Rest of South America Market Status and Outlook (2017-2027)
4.5. Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, South Africa and Rest of MEA)
4.5.1. Saudi Arabia Market Status and Outlook (2017-2027)
4.5.2. United Arab Emirates Market Status and Outlook (2017-2027)
4.5.3. Egypt Market Status and Outlook (2017-2027)
4.5.4. Nigeria Market Status and Outlook (2017-2027)
4.5.5. South Africa Market Status and Outlook (2017-2027)
4.5.6. Turkey Market Status and Outlook (2017-2027)
4.5.7. Rest of Middle East and Africa Market Status and Outlook (2017-2027)
5. Prostate-specific Antigen (PSA) Testing Market, By Type
5.1. Introduction
5.2. Global Prostate-specific Antigen (PSA) Testing Revenue and Market Share by Type (2017-2021)
5.2.1. Global Prostate-specific Antigen (PSA) Testing Revenue and Revenue Share by Type (2017-2021)
5.3. CLIA Method
5.3.1. Global CLIA Method Revenue and Growth Rate (2017-2021)
5.4. ELISA Method
5.4.1. Global ELISA Method Revenue and Growth Rate (2017-2021)
6. Prostate-specific Antigen (PSA) Testing Market, By Applications
6.1. Introduction
6.2. Global Prostate-specific Antigen (PSA) Testing Revenue and Market Share by Applications (2017-2021)
6.2.1. Global Prostate-specific Antigen (PSA) Testing Revenue and Revenue Share by Applications (2017-2021)
6.3. Screening
6.3.1. Global Screening Revenue and Growth Rate (2017-2021)
6.4. Post-treatment Monitoring
6.4.1. Global Post-treatment Monitoring Revenue and Growth Rate (2017-2021)
6.5. Other
6.5.1. Global Other Revenue and Growth Rate (2017-2021)
7. Prostate-specific Antigen (PSA) Testing Market, By Region
7.1. Introduction
7.2. Global Prostate-specific Antigen (PSA) Testing Revenue and Market Share by Regions
7.2.1. Global Prostate-specific Antigen (PSA) Testing Revenue by Regions (2017-2021)
7.3. North America Prostate-specific Antigen (PSA) Testing by Countries
7.3.1. North America Prostate-specific Antigen (PSA) Testing Revenue and Growth Rate (2017-2021)
7.3.2. North America Prostate-specific Antigen (PSA) Testing Revenue (Million USD) by Countries (2017-2021)
7.3.3. United States
7.3.3.1. United States Prostate-specific Antigen (PSA) Testing Revenue (Millions USD) and Growth Rate (2017-2021)
7.3.4. Canada
7.3.4.1. Canada Prostate-specific Antigen (PSA) Testing Revenue (Millions USD) and Growth Rate (2017-2021)
7.3.5. Mexico
7.3.5.1. Mexico Prostate-specific Antigen (PSA) Testing Revenue (Millions USD) and Growth Rate (2017-2021)
7.4. Europe Prostate-specific Antigen (PSA) Testing by Countries
7.4.1. Europe Prostate-specific Antigen (PSA) Testing Revenue and Growth Rate (2017-2021)
7.4.2. Europe Prostate-specific Antigen (PSA) Testing Revenue (Million USD) by Countries (2017-2021)
7.4.3. Germany
7.4.3.1. Germany Prostate-specific Antigen (PSA) Testing Revenue (Millions USD) and Growth Rate (2017-2021)
7.4.4. France
7.4.4.1. France Prostate-specific Antigen (PSA) Testing Revenue (Millions USD) and Growth Rate (2017-2021)
7.4.5. UK
7.4.5.1. UK Prostate-specific Antigen (PSA) Testing Revenue (Millions USD) and Growth Rate (2017-2021)
7.4.6. Russia
7.4.6.1. Russia Prostate-specific Antigen (PSA) Testing Revenue (Millions USD) and Growth Rate (2017-2021)
7.4.7. Italy
7.4.7.1. Italy Prostate-specific Antigen (PSA) Testing Revenue (Millions USD) and Growth Rate (2017-2021)
7.4.8. Rest of Europe
7.4.8.1. Rest of Europe Prostate-specific Antigen (PSA) Testing Revenue (Millions USD) and Growth Rate (2017-2021)
7.5. Asia-Pacific Prostate-specific Antigen (PSA) Testing by Countries
7.5.1. Asia-Pacific Prostate-specific Antigen (PSA) Testing Revenue and Growth Rate (2017-2021)
7.5.2. Asia-Pacific Prostate-specific Antigen (PSA) Testing Revenue (Million USD) by Countries (2017-2021)
7.5.3. China
7.5.3.1. China Prostate-specific Antigen (PSA) Testing Revenue (Millions USD) and Growth Rate (2017-2021)
7.5.4. Japan
7.5.4.1. Japan Prostate-specific Antigen (PSA) Testing Revenue (Millions USD) and Growth Rate (2017-2021)
7.5.5. Korea
7.5.5.1. Korea Prostate-specific Antigen (PSA) Testing Revenue (Millions USD) and Growth Rate (2017-2021)
7.5.6. India
7.5.6.1. India Prostate-specific Antigen (PSA) Testing Revenue (Millions USD) and Growth Rate (2017-2021)
7.5.7. Southeast Asia
7.5.7.1. Southeast Asia Prostate-specific Antigen (PSA) Testing Revenue (Millions USD) and Growth Rate (2017-2021)
7.5.8. Rest of Asia-Pacific
7.5.8.1. Rest of Asia-Pacific Prostate-specific Antigen (PSA) Testing Revenue (Millions USD) and Growth Rate (2017-2021)
7.6. South America Prostate-specific Antigen (PSA) Testing by Countries
7.6.1. South America Prostate-specific Antigen (PSA) Testing Revenue and Growth Rate (2017-2021)
7.6.2. South America Prostate-specific Antigen (PSA) Testing Revenue (Million USD) by Countries (2017-2021)
7.6.3. Brazil
7.6.3.1. Brazil Prostate-specific Antigen (PSA) Testing Revenue (Millions USD) and Growth Rate (2017-2021)
7.6.4. Argentina
7.6.4.1. Argentina Prostate-specific Antigen (PSA) Testing Revenue (Millions USD) and Growth Rate (2017-2021)
7.6.5. Columbia
7.6.5.1. Columbia Prostate-specific Antigen (PSA) Testing Revenue (Millions USD) and Growth Rate (2017-2021)
7.6.6. Rest of South America
7.6.6.1. Rest of South America Prostate-specific Antigen (PSA) Testing Revenue (Millions USD) and Growth Rate (2017-2021)
7.7. Middle East and Africa Prostate-specific Antigen (PSA) Testing by Countries
7.7.1. Middle East and Africa Prostate-specific Antigen (PSA) Testing Revenue and Growth Rate (2017-2021)
7.7.2. Middle East and Africa Prostate-specific Antigen (PSA) Testing Revenue (Million USD) by Countries (2017-2021)
7.7.3. Saudi Arabia
7.7.3.1. Saudi Arabia Prostate-specific Antigen (PSA) Testing Revenue (Millions USD) and Growth Rate (2017-2021)
7.7.4. United Arab Emirates
7.7.4.1. United Arab Emirates Prostate-specific Antigen (PSA) Testing Revenue (Millions USD) and Growth Rate (2017-2021)
7.7.5. Egypt
7.7.5.1. Egypt Prostate-specific Antigen (PSA) Testing Revenue (Millions USD) and Growth Rate (2017-2021)
7.7.6. Nigeria
7.7.6.1. Nigeria Prostate-specific Antigen (PSA) Testing Revenue (Millions USD) and Growth Rate (2017-2021)
7.7.7. South Africa
7.7.7.1. South Africa Prostate-specific Antigen (PSA) Testing Revenue (Millions USD) and Growth Rate (2017-2021)
7.7.8. Turkey
7.7.8.1. Turkey Prostate-specific Antigen (PSA) Testing Revenue (Millions USD) and Growth Rate (2017-2021)
7.7.9. Rest of Middle East and Africa
7.7.9.1. Rest of Middle East and Africa Prostate-specific Antigen (PSA) Testing Revenue (Millions USD) and Growth Rate (2017-2021)
8. Company Profiles
8.1. Abbott
8.1.1. Business Overview
8.1.2. Service Portfolio
8.1.3. Strategic Developments
8.1.4. Financial Overview
8.2. Boston Scientific Corporation
8.2.1. Business Overview
8.2.2. Service Portfolio
8.2.3. Strategic Developments
8.2.4. Financial Overview
8.3. Bayer AG
8.3.1. Business Overview
8.3.2. Service Portfolio
8.3.3. Strategic Developments
8.3.4. Financial Overview
8.4. Siemens Healthcare
8.4.1. Business Overview
8.4.2. Service Portfolio
8.4.3. Strategic Developments
8.4.4. Financial Overview
8.5. DiaSorin
8.5.1. Business Overview
8.5.2. Service Portfolio
8.5.3. Strategic Developments
8.5.4. Financial Overview
8.6. Roche
8.6.1. Business Overview
8.6.2. Service Portfolio
8.6.3. Strategic Developments
8.6.4. Financial Overview
8.7. Beckman Coulter
8.7.1. Business Overview
8.7.2. Service Portfolio
8.7.3. Strategic Developments
8.7.4. Financial Overview
8.8. PerkinElmer
8.8.1. Business Overview
8.8.2. Service Portfolio
8.8.3. Strategic Developments
8.8.4. Financial Overview
8.9. Tosoh
8.9.1. Business Overview
8.9.2. Service Portfolio
8.9.3. Strategic Developments
8.9.4. Financial Overview
9. Prostate-specific Antigen (PSA) Testing Market Forecast (2022-2027)
9.1. Global Prostate-specific Antigen (PSA) Testing Revenue (Millions USD) and Growth Rate (2022-2027)
9.2. Prostate-specific Antigen (PSA) Testing Market Forecast by Regions (2022-2027)
9.2.1. North America Prostate-specific Antigen (PSA) Testing Market Forecast (2022-2027)
9.2.1.1. United States Prostate-specific Antigen (PSA) Testing Market Forecast (2022-2027)
9.2.1.2. Canada Prostate-specific Antigen (PSA) Testing Market Forecast (2022-2027)
9.2.1.3. Mexico Prostate-specific Antigen (PSA) Testing Market Forecast (2022-2027)
9.2.2. Europe Prostate-specific Antigen (PSA) Testing Market Forecast (2022-2027)
9.2.2.1. Germany Prostate-specific Antigen (PSA) Testing Market Forecast (2022-2027)
9.2.2.2. France Prostate-specific Antigen (PSA) Testing Market Forecast (2022-2027)
9.2.2.3. UK Prostate-specific Antigen (PSA) Testing Market Forecast (2022-2027)
9.2.2.4. Russia Prostate-specific Antigen (PSA) Testing Market Forecast (2022-2027)
9.2.2.5. Italy Prostate-specific Antigen (PSA) Testing Market Forecast (2022-2027)
9.2.2.6. Rest of Europe Prostate-specific Antigen (PSA) Testing Market Forecast (2022-2027)
9.2.3. Asia-Pacific Prostate-specific Antigen (PSA) Testing Market Forecast (2022-2027)
9.2.3.1. China Prostate-specific Antigen (PSA) Testing Market Forecast (2022-2027)
9.2.3.2. Japan Prostate-specific Antigen (PSA) Testing Market Forecast (2022-2027)
9.2.3.3. Korea Prostate-specific Antigen (PSA) Testing Market Forecast (2022-2027)
9.2.3.4. India Prostate-specific Antigen (PSA) Testing Market Forecast (2022-2027)
9.2.3.5. Southeast Asia Prostate-specific Antigen (PSA) Testing Market Forecast (2022-2027)
9.2.3.6. Rest of Asia-Pacific Prostate-specific Antigen (PSA) Testing Market Forecast (2022-2027)
9.2.4. South America Prostate-specific Antigen (PSA) Testing Market Forecast (2022-2027)
9.2.4.1. Brazil Prostate-specific Antigen (PSA) Testing Market Forecast (2022-2027)
9.2.4.2. Argentina Prostate-specific Antigen (PSA) Testing Market Forecast (2022-2027)
9.2.4.3. Columbia Prostate-specific Antigen (PSA) Testing Market Forecast (2022-2027)
9.2.4.4. Rest of South America Prostate-specific Antigen (PSA) Testing Market Forecast (2022-2027)
9.2.5. Middle East and Africa Prostate-specific Antigen (PSA) Testing Market Forecast (2022-2027)
9.2.5.1. Saudi Arabia Prostate-specific Antigen (PSA) Testing Market Forecast (2022-2027)
9.2.5.2. United Arab Emirates Prostate-specific Antigen (PSA) Testing Market Forecast (2022-2027)
9.2.5.3. Egypt Prostate-specific Antigen (PSA) Testing Market Forecast (2022-2027)
9.2.5.4. Nigeria Prostate-specific Antigen (PSA) Testing Market Forecast (2022-2027)
9.2.5.5. South Africa Prostate-specific Antigen (PSA) Testing Market Forecast (2022-2027)
9.2.5.6. Turkey Prostate-specific Antigen (PSA) Testing Market Forecast (2022-2027)
9.2.5.7. Rest of Middle East and Africa Prostate-specific Antigen (PSA) Testing Market Forecast (2022-2027)
9.3. Prostate-specific Antigen (PSA) Testing Market Forecast by Type (2022-2027)
9.3.1. Prostate-specific Antigen (PSA) Testing Forecast by Type (2022-2027)
9.3.2. Prostate-specific Antigen (PSA) Testing Market Share Forecast by Type (2022-2027)
9.4. Prostate-specific Antigen (PSA) Testing Market Forecast by Applications (2022-2027)
9.4.1. Prostate-specific Antigen (PSA) Testing Forecast by Applications (2022-2027)
9.4.2. Prostate-specific Antigen (PSA) Testing Market Share Forecast by Applications (2022-2027)
List of Tables
List of Tables and Figures:
Figure United States Prostate-specific Antigen (PSA) Testing Revenue (Million USD) and Growth Rate (2017-2027)
Figure Canada Prostate-specific Antigen (PSA) Testing Revenue (Million USD) and Growth Rate (2017-2027)
Figure Mexico Prostate-specific Antigen (PSA) Testing Revenue (Million USD) and Growth Rate (2017-2027)
Figure Germany Prostate-specific Antigen (PSA) Testing Revenue (Million USD) and Growth Rate (2017-2027)
Figure France Prostate-specific Antigen (PSA) Testing Revenue (Million USD) and Growth Rate (2017-2027)
Figure UK Prostate-specific Antigen (PSA) Testing Revenue (Million USD) and Growth Rate (2017-2027)
Figure Russia Prostate-specific Antigen (PSA) Testing Revenue (Million USD) and Growth Rate (2017-2027)
Figure Italy Prostate-specific Antigen (PSA) Testing Revenue (Million USD) and Growth Rate (2017-2027)
Figure Rest of Europe Prostate-specific Antigen (PSA) Testing Revenue (Million USD) and Growth Rate (2017-2027)
Figure China Prostate-specific Antigen (PSA) Testing Revenue (Million USD) and Growth Rate (2017-2027)
Figure Japan Prostate-specific Antigen (PSA) Testing Revenue (Million USD) and Growth Rate (2017-2027)
Figure Korea Prostate-specific Antigen (PSA) Testing Revenue (Million USD) and Growth Rate (2017-2027)
Figure India Prostate-specific Antigen (PSA) Testing Revenue (Million USD) and Growth Rate (2017-2027)
Figure Southeast Asia Prostate-specific Antigen (PSA) Testing Revenue (Million USD) and Growth Rate (2017-2027)
Figure Rest of Asia-Pacific Prostate-specific Antigen (PSA) Testing Revenue (Million USD) and Growth Rate (2017-2027)
Figure Brazil Prostate-specific Antigen (PSA) Testing Revenue (Million USD) and Growth Rate (2017-2027)
Figure Argentina Prostate-specific Antigen (PSA) Testing Revenue (Million USD) and Growth Rate (2017-2027)
Figure Columbia Prostate-specific Antigen (PSA) Testing Revenue (Million USD) and Growth Rate (2017-2027)
Figure Rest of South America Prostate-specific Antigen (PSA) Testing Revenue (Million USD) and Growth Rate (2017-2027)
Figure Saudi Arabia Prostate-specific Antigen (PSA) Testing Revenue (Million USD) and Growth Rate (2017-2027)
Figure United Arab Emirates Prostate-specific Antigen (PSA) Testing Revenue (Million USD) and Growth Rate (2017-2027)
Figure Egypt Prostate-specific Antigen (PSA) Testing Revenue (Million USD) and Growth Rate (2017-2027)
Figure Nigeria Prostate-specific Antigen (PSA) Testing Revenue (Million USD) and Growth Rate (2017-2027)
Figure South Africa Prostate-specific Antigen (PSA) Testing Revenue (Million USD) and Growth Rate (2017-2027)
Figure Turkey Prostate-specific Antigen (PSA) Testing Revenue (Million USD) and Growth Rate (2017-2027)
Figure Rest of Middle East and Africa Prostate-specific Antigen (PSA) Testing Revenue (Million USD) and Growth Rate (2017-2027)
Table Global Prostate-specific Antigen (PSA) Testing Revenue and Revenue Share by Type (2017-2019)
Figure Global CLIA Method Revenue and Growth Rate (2017-2019)
Figure Global ELISA Method Revenue and Growth Rate (2017-2019)
Table Global Prostate-specific Antigen (PSA) Testing Revenue and Revenue Share by Applications (2017-2019)
Figure Global Screening Revenue and Growth Rate (2017-2019)
Figure Global Post-treatment Monitoring Revenue and Growth Rate (2017-2019)
Figure Global Other Revenue and Growth Rate (2017-2019)
Table Global Prostate-specific Antigen (PSA) Testing Revenue by Regions (2017-2019)
Figure North America Prostate-specific Antigen (PSA) Testing Growth Rate (2017-2019)
Figure North America Prostate-specific Antigen (PSA) Testing Revenue and Growth Rate (2017-2019)
Figure North America Prostate-specific Antigen (PSA) Testing by Countries (2017-2019)
Figure North America Prostate-specific Antigen (PSA) Testing Revenue (Million USD) by Countries (2017-2019)
Figure United States Prostate-specific Antigen (PSA) Testing Growth Rate (2017-2019)
Figure United States Prostate-specific Antigen (PSA) Testing Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Canada Prostate-specific Antigen (PSA) Testing Growth Rate (2017-2019)
Figure Canada Prostate-specific Antigen (PSA) Testing Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Mexico Prostate-specific Antigen (PSA) Testing Growth Rate (2017-2019)
Figure Mexico Prostate-specific Antigen (PSA) Testing Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Europe Prostate-specific Antigen (PSA) Testing Growth Rate (2017-2019)
Figure Europe Prostate-specific Antigen (PSA) Testing Revenue and Growth Rate (2017-2019)
Figure Europe Prostate-specific Antigen (PSA) Testing by Countries (2017-2019)
Figure Europe Prostate-specific Antigen (PSA) Testing Revenue (Million USD) by Countries (2017-2019)
Figure Germany Prostate-specific Antigen (PSA) Testing Growth Rate (2017-2019)
Figure Germany Prostate-specific Antigen (PSA) Testing Revenue (Millions USD) and Growth Rate (2017-2019)
Figure France Prostate-specific Antigen (PSA) Testing Growth Rate (2017-2019)
Figure France Prostate-specific Antigen (PSA) Testing Revenue (Millions USD) and Growth Rate (2017-2019)
Figure UK Prostate-specific Antigen (PSA) Testing Growth Rate (2017-2019)
Figure UK Prostate-specific Antigen (PSA) Testing Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Russia Prostate-specific Antigen (PSA) Testing Growth Rate (2017-2019)
Figure Russia Prostate-specific Antigen (PSA) Testing Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Italy Prostate-specific Antigen (PSA) Testing Growth Rate (2017-2019)
Figure Italy Prostate-specific Antigen (PSA) Testing Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Rest of Europe Prostate-specific Antigen (PSA) Testing Growth Rate (2017-2019)
Figure Rest of Europe Prostate-specific Antigen (PSA) Testing Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Asia-Pacific Prostate-specific Antigen (PSA) Testing Growth Rate (2017-2019)
Figure Asia-Pacific Prostate-specific Antigen (PSA) Testing Revenue and Growth Rate (2017-2019)
Figure Asia-Pacific Prostate-specific Antigen (PSA) Testing by Countries (2017-2019)
Figure Asia-Pacific Prostate-specific Antigen (PSA) Testing Revenue (Million USD) by Countries (2017-2019)
Figure China Prostate-specific Antigen (PSA) Testing Growth Rate (2017-2019)
Figure China Prostate-specific Antigen (PSA) Testing Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Japan Prostate-specific Antigen (PSA) Testing Growth Rate (2017-2019)
Figure Japan Prostate-specific Antigen (PSA) Testing Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Korea Prostate-specific Antigen (PSA) Testing Growth Rate (2017-2019)
Figure Korea Prostate-specific Antigen (PSA) Testing Revenue (Millions USD) and Growth Rate (2017-2019)
Figure India Prostate-specific Antigen (PSA) Testing Growth Rate (2017-2019)
Figure India Prostate-specific Antigen (PSA) Testing Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Southeast Asia Prostate-specific Antigen (PSA) Testing Growth Rate (2017-2019)
Figure Southeast Asia Prostate-specific Antigen (PSA) Testing Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Rest of Asia-Pacific Prostate-specific Antigen (PSA) Testing Growth Rate (2017-2019)
Figure Rest of Asia-Pacific Prostate-specific Antigen (PSA) Testing Revenue (Millions USD) and Growth Rate (2017-2019)
Figure South America Prostate-specific Antigen (PSA) Testing Growth Rate (2017-2019)
Figure South America Prostate-specific Antigen (PSA) Testing Revenue and Growth Rate (2017-2019)
Figure South America Prostate-specific Antigen (PSA) Testing by Countries (2017-2019)
Figure South America Prostate-specific Antigen (PSA) Testing Revenue (Million USD) by Countries (2017-2019)
Figure Brazil Prostate-specific Antigen (PSA) Testing Growth Rate (2017-2019)
Figure Brazil Prostate-specific Antigen (PSA) Testing Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Argentina Prostate-specific Antigen (PSA) Testing Growth Rate (2017-2019)
Figure Argentina Prostate-specific Antigen (PSA) Testing Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Columbia Prostate-specific Antigen (PSA) Testing Growth Rate (2017-2019)
Figure Columbia Prostate-specific Antigen (PSA) Testing Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Rest of South America Prostate-specific Antigen (PSA) Testing Growth Rate (2017-2019)
Figure Rest of South America Prostate-specific Antigen (PSA) Testing Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Middle East and Africa Prostate-specific Antigen (PSA) Testing Growth Rate (2017-2019)
Figure Middle East and Africa Prostate-specific Antigen (PSA) Testing Revenue and Growth Rate (2017-2019)
Figure Middle East and Africa Prostate-specific Antigen (PSA) Testing by Countries (2017-2019)
Figure Middle East and Africa Prostate-specific Antigen (PSA) Testing Revenue (Million USD) by Countries (2017-2019)
Figure Saudi Arabia Prostate-specific Antigen (PSA) Testing Growth Rate (2017-2019)
Figure Saudi Arabia Prostate-specific Antigen (PSA) Testing Revenue (Millions USD) and Growth Rate (2017-2019)
Figure United Arab Emirates Prostate-specific Antigen (PSA) Testing Growth Rate (2017-2019)
Figure United Arab Emirates Prostate-specific Antigen (PSA) Testing Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Egypt Prostate-specific Antigen (PSA) Testing Growth Rate (2017-2019)
Figure Egypt Prostate-specific Antigen (PSA) Testing Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Nigeria Prostate-specific Antigen (PSA) Testing Growth Rate (2017-2019)
Figure Nigeria Prostate-specific Antigen (PSA) Testing Revenue (Millions USD) and Growth Rate (2017-2019)
Figure South Africa Prostate-specific Antigen (PSA) Testing Growth Rate (2017-2019)
Figure South Africa Prostate-specific Antigen (PSA) Testing Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Turkey Prostate-specific Antigen (PSA) Testing Growth Rate (2017-2019)
Figure Turkey Prostate-specific Antigen (PSA) Testing Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Rest of Middle East and Africa Prostate-specific Antigen (PSA) Testing Growth Rate (2017-2019)
Figure Rest of Middle East and Africa Prostate-specific Antigen (PSA) Testing Revenue (Millions USD) and Growth Rate (2017-2019)
Table Abbott Prostate-specific Antigen (PSA) Testing Financial Overview
Table Boston Scientific Corporation Prostate-specific Antigen (PSA) Testing Financial Overview
Table Bayer AG Prostate-specific Antigen (PSA) Testing Financial Overview
Table Siemens Healthcare Prostate-specific Antigen (PSA) Testing Financial Overview
Table DiaSorin Prostate-specific Antigen (PSA) Testing Financial Overview
Table Roche Prostate-specific Antigen (PSA) Testing Financial Overview
Table Beckman Coulter Prostate-specific Antigen (PSA) Testing Financial Overview
Table PerkinElmer Prostate-specific Antigen (PSA) Testing Financial Overview
Table Tosoh Prostate-specific Antigen (PSA) Testing Financial Overview
Figure Global Prostate-specific Antigen (PSA) Testing Revenue (Millions USD) and Growth Rate (2019-2027)
Table Prostate-specific Antigen (PSA) Testing Market Forecast by Regions (2019-2027)
Figure North America Prostate-specific Antigen (PSA) Testing Market Forecast (2019-2027)
Figure United States Prostate-specific Antigen (PSA) Testing Market Forecast (2019-2027)
Figure Canada Prostate-specific Antigen (PSA) Testing Market Forecast (2019-2027)
Figure Mexico Prostate-specific Antigen (PSA) Testing Market Forecast (2019-2027)
Figure Europe Prostate-specific Antigen (PSA) Testing Market Forecast (2019-2027)
Figure Germany Prostate-specific Antigen (PSA) Testing Market Forecast (2019-2027)
Figure France Prostate-specific Antigen (PSA) Testing Market Forecast (2019-2027)
Figure UK Prostate-specific Antigen (PSA) Testing Market Forecast (2019-2027)
Figure Russia Prostate-specific Antigen (PSA) Testing Market Forecast (2019-2027)
Figure Italy Prostate-specific Antigen (PSA) Testing Market Forecast (2019-2027)
Figure Rest of Europe Prostate-specific Antigen (PSA) Testing Market Forecast (2019-2027)
Figure Asia-Pacific Prostate-specific Antigen (PSA) Testing Market Forecast (2019-2027)
Figure China Prostate-specific Antigen (PSA) Testing Market Forecast (2019-2027)
Figure Japan Prostate-specific Antigen (PSA) Testing Market Forecast (2019-2027)
Figure Korea Prostate-specific Antigen (PSA) Testing Market Forecast (2019-2027)
Figure India Prostate-specific Antigen (PSA) Testing Market Forecast (2019-2027)
Figure Southeast Asia Prostate-specific Antigen (PSA) Testing Market Forecast (2019-2027)
Figure Rest of Asia-Pacific Prostate-specific Antigen (PSA) Testing Market Forecast (2019-2027)
Figure South America Prostate-specific Antigen (PSA) Testing Market Forecast (2019-2027)
Figure Brazil Prostate-specific Antigen (PSA) Testing Market Forecast (2019-2027)
Figure Argentina Prostate-specific Antigen (PSA) Testing Market Forecast (2019-2027)
Figure Columbia Prostate-specific Antigen (PSA) Testing Market Forecast (2019-2027)
Figure Rest of South America Prostate-specific Antigen (PSA) Testing Market Forecast (2019-2027)
Figure Middle East and Africa Prostate-specific Antigen (PSA) Testing Market Forecast (2019-2027)
Figure Saudi Arabia Prostate-specific Antigen (PSA) Testing Market Forecast (2019-2027)
Figure United Arab Emirates Prostate-specific Antigen (PSA) Testing Market Forecast (2019-2027)
Figure Egypt Prostate-specific Antigen (PSA) Testing Market Forecast (2019-2027)
Figure Nigeria Prostate-specific Antigen (PSA) Testing Market Forecast (2019-2027)
Figure South Africa Prostate-specific Antigen (PSA) Testing Market Forecast (2019-2027)
Figure Turkey Prostate-specific Antigen (PSA) Testing Market Forecast (2019-2027)
Figure Rest of Middle East and Africa Prostate-specific Antigen (PSA) Testing Market Forecast (2019-2027)
Figure Global Prostate-specific Antigen (PSA) Testing Forecast by Type (2019-2027)
Figure Global Prostate-specific Antigen (PSA) Testing Market Share Forecast by Type (2019-2027)
Figure Global Prostate-specific Antigen (PSA) Testing Forecast by Type (2019-2027)
Figure Global Prostate-specific Antigen (PSA) Testing Forecast by Applications (2019-2027)
Figure Global Prostate-specific Antigen (PSA) Testing Market Share Forecast by Applications (2019-2027)
Figure Global Prostate-specific Antigen (PSA) Testing Forecast by Applications (2019-2027)
Please Note: Data related to the Companies are subject to Availability.
Research Methodology
We use both primary as well as secondary research for our market surveys, estimates and for developing forecast. Our research process commence by analyzing the problem which enable us to design the scope for our research study. Our research process is uniquely designed with enough flexibility to adjust according to changing nature of products and markets, while retaining core element to ensure reliability and accuracy in research findings. We understand both macro and micro-economic factors to evaluate and forecast different market segments.
Data Mining
Data is extensively collected through various secondary sources such as annual reports, investor presentations, SEC filings, and other corporate publications. We also refer trade magazines, technical journals, paid databases such as Factiva and Bloomberg, industry trade journals, scientific journals, and social media data to understand market dynamics and industry trends. Further, we also conduct primary research to understand market drivers, restraints, opportunities, challenges, and competitive scenario to build our analysis.
Data Collection Matrix
|
Data Collection Matrix |
Supply Side |
Demand Side |
|
Primary Data Sources |
|
|
|
Secondary Data Sources |
|
|
Market Modeling and Forecasting
We use epidemiology and capital equipment-based models to forecast market size of different segments at country and regional level.
- Epidemiology-based Forecasting Model: This method uses epidemiology data gathered through various publications and from physicians to estimate population of patients, flow of treatment of individual disease and therapies. The data collected through this method includes statics on incidence of disease, population suffering from disease, and treatment population. This method is used to understand:
- Number of patients for particular device or medical procedure and
- Repeated use of particular device depending on health and condition of patient
- Capital-based Forecasting Model: This method of forecasting is based on number of replacements, installed-based and new sales of capital equipment used in various healthcare and diagnostic centers. These three parameters are calculated and forecast is developed. Installation base is calculated as average number of units per facility; while sales for particular year is calculated from number of new and replace units. Secondary data is collected through various supply chain intermediaries and opinion leaders to arrive at installation and sales rate. These techniques help our analysts in validating market and developed market estimates and forecast.
We do forecast on basis of several parameters such as market drivers, market opportunities, industry trends government regulations, raw materials supply and trade dynamics to ensure relevance of forecast with market scenario. With increasing need to granulized information, we used bottom-up methodology for forecasting where we evaluate each regional segment differently and combined all forecast to develop final market forecast.
Data Validation
We believe primary research is a very important tool in analyzing and forecasting different markets. In order to make sure accuracy of our findings, our team conducts primary interviews at every stage of research to gain deep insights into current business environment and future trends and key developments in market. This includes use of various methods such as telephonic interviews, focus groups, face to face interviews and questionnaires to validate our research from all aspects. We validate our data through primary research from key industry leaders such as CEO, product managers, marketing managers, suppliers, distributors, and consumers are frequently interviewed. These interviews provide valuable insights which help us to have better market understanding besides validating our estimates and forecast.
Data Triangulation
Industry Analysis
|
Qualitative Data |
Quantitative Data (2017-2025) |
|
|